The New Product Planning Manager is a high impact role that will support the strategy, planning and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position will report to the Director of New Product Planning.
This role will be hybrid 2-3 days a week based at Genesis’s San Diego office.
Key Responsibilities:
Market analysis: Analyze disease areas, treatment paradigms, and unmet needs to help shape the positioning of new potential drugs
Primary and secondary research: Support KOL interviews, along with secondary research such as epidemiology and published literature, to build and validate commercial assumptions
Competitive monitoring: Track competitor pipelines, clinical readouts, approvals, and deals, including monitoring conference abstracts and presentations for early signals, and translate the implications into updated assumptions for the team
Development strategy: Contribute commercial input into Target Product Profiles (TPPs) and clinical development plans (endpoints, comparators, patient populations, and indication sequencing)
Cross-functional collaboration: Work with discovery, preclinical development, business development, and finance to keep programs aligned with commercial objectives
Candidate profile:
Life sciences background, ideally a BS or MS degree in biology or a related field
1-2 years at a top-tier consulting firm, investment bank, or equity research group preferred
Experience in New Product Planning, marketing, portfolio strategy, competitive intelligence, or a related analytical role at a pharmaceutical or biotech company also considered
Experience in oncology or immunology is a plus
Some exposure to commercial assessments based on primary and secondary research, ideally for preclinical and early clinical assets
Strong Excel modeling and PowerPoint skills
Excellent communication, listening, and presentation skills
Ability to travel domestically and internationally, if required, approximately 10% of the time
About Genesis Molecular AI
Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. Genesis has also signed category-leading AI-pharma deals, the most recent of which was a significant expansion with Incyte (see coverage in Forbes and GEN) with a total potential deal value of several billion dollars.
Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Skills Required
- Life sciences background
- BS or MS degree in biology or related field
- 1-2 years at a consulting firm, investment bank, or equity research group
- Experience in new product planning, marketing, portfolio strategy, or competitive intelligence at a pharmaceutical or biotech company
- Exposure to commercial assessments using primary and secondary research for preclinical and early clinical assets
- Experience in oncology or immunology
- Strong Excel modeling skills
- Strong PowerPoint skills
- Excellent communication, listening, and presentation skills
- Ability to travel domestically and internationally (~10%)
- Based at Genesis physical office in San Diego
What We Do
Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.
